The treatment of gastric cancer (GC) is a significant global health challenge, and N6-methyladenosine (m6A) has been found to play a key role in tumor progression.
METTL5, a methyltransferase linked to m6A, has been shown to be upregulated in GC, suggesting that higher levels of METTL5 are associated with poor patient outcomes and advanced cancer characteristics.
The study conducted a series of experiments including cell assays and animal models, demonstrating that METTL5 promotes GC cell proliferation, migration, and invasion, while also affecting sphingomyelin metabolism and the cell's sensitivity to cisplatin.